Bashashati M, et al. – Experts here tried to assess the impact of interleukin-6 in irritable bowel syndrome (IBS). A pro-inflammatory phenotype was demonstrated by the higher interleukin-6 (IL-6) levels in IBS and more specifically in diarrhea predominant IBS (IBS-D) in these patients. Moreover, this phenomenon was not supported by the polymorphism of IL-6 (-G174C). Increased IL-6 in IBS seemed to be an acquired phenomenon or mediated by other genotypes. A new opportunity for personalized anti-inflammatory therapies of IBS would be introduced by categorizing patients based on their circulating IL-6 levels.